Pushing the Boundaries of Drug Design to Discover Novel Selective BBB Permeable Kinase Inhibitions as Novel Therapies for Neurological Diseases

Time: 9:00 am
day: Day Two


  • Understanding the role of the immune system neurological diseases such as Amyotrophic Lateral Sclerosis (ALS), Parkinson’s, Alzheimer’s (AD), and Multiple sclerosis (MS) to discover new therapies
  • Targeting kinases in the CNS to identify clinically validated mechanisms and pathways to expand on the existing biological and clinical knowledge to further our understanding of the causative vs. the consequential effect of the immune system on neurodegeneration
  • Utilizing Structure-Based Drug Design (SBDD), Parallel Medicinal Chemistry (PMC) and Computer Aid Drug Design (CADD) to optimize the physicochemical properties of small molecules inhibitors to enhance brain exposures to treat neurological diseases
  • Discovering novel kinase inhibitors that exhibit excellent kinome selectivity and BBB permeability yet fall outside the drug-like space traditionally targeted when optimizing for improved CNS properties